Submission to the Misuse of Drugs Amendment Bill September Society and its Role and Functions. 29 September 2010
|
|
- Cleopatra Marshall
- 6 years ago
- Views:
Transcription
1 PHARMACY HOUSE 124 DIXON STREET PO BOX WELLINGTON NEW ZEALAND TELEPHONE FAX WEBSITE 29 September 2010 Clerk of the Health Committee Select Committee Secretariat Parliament Buildings Wellington Submission to the Misuse of Drugs Amendment Bill 2010 from the Pharmaceutical Society of New Zealand September 2010 The Pharmaceutical Society and its Role and Functions The Pharmaceutical Society of New Zealand Inc is the professional association representing over 3,000 pharmacists, from all sectors of practice (community, hospital, academic, industry and PHOs). We provide to pharmacists professional support and representation, training for continuing professional development, and assistance to enable them to deliver to all New Zealanders the best pharmaceutical practice and professional services in relation to medicines. The Society focuses on the important role pharmacists have in medicines management and in the safe and quality use of medicines. The Society wishes to appear before the Select Committee and make oral submissions. Those who would like to appear are: Chief Executive Mr Richard Townley, and Chief Pharmacist Advisor Mr Euan Galloway. Contact details are; Mr Euan Galloway Pharmaceutical Society of New Zealand Inc 124 Dixon Street PO Box Wellington Phone:
2 Clause 6 To Reclassify Ephedrine and Pseudoephedrine Controlled Drugs as Class B2 The Pharmaceutical Society appreciates the reason why the government wishes to impose stricter controls on the supply of these medicines which are currently Class C controlled drugs. We acknowledge there is currently a major social problem with methamphetamine (P) misuse, but respectfully point out that it is methamphetamine that is the problem, not pseudoephedrine. The diversion of pseudoephedrine for illicit drug manufacture is of concern to pharmacists, as it is to the whole community. Ephedrine is currently a Class C5 controlled drug which requires the prescription of an authorised prescriber (such as a doctor) before it can be supplied or administered to any person. It currently has no therapeutic use, though in the past has been used to treat asthma and, inappropriately, by bodybuilders to burn off unwanted body fat. The Pharmaceutical Society has no interest in ephedrine and we will concentrate our submission on pseudoephedrine (PSE). Pseudoephedrine is currently a Class C3 controlled drug and sustained release forms are Class C5. Both ordinary and sustained release formulations have supply exemptions through the definition of a 'partially exempted drug' in regulation 2 of the Misuse of Drugs Regulations The Pharmaceutical Society queries the need for Parliament to use a Misuse of Drugs Amendment Bill to control the supply of pseudoephedrine. Most members speaking in the first reading of this Bill spoke of the reclassification having the effect of removing the over the counter (OTC) availability of preparations containing pseudoephedrine from pharmacies which will ensure that it is available only with a prescription from a medical practitioner. This was also stated in the recently published Report on Organised Crime in NZ 2010 "Forthcoming legislative changes that intend to make pseudoephedrine a prescription only medicine aim to significantly reduce domestic diversion." If that is the intent of the Bill a better method could be to, by Order in Council, revoke regulation 20(3) of the Misuse of Drugs Regulations 1977 and, consequently, amend regulation 20(2)(a) and subsection (b) of the 'partially exempted drug' interpretation in regulation 2. It is regulation 20(3) that permits pseudoephedrine in the current OTC cough and cold preparations to be sold in the circumstances set out in the definition of 'pharmacy only medicine' in section 3 of the Medicines Act Without regulation 20(3) and the extended definition of a partially exempted drug, pseudoephedrine has to be prescribed by an authorised prescriber. Shifting pseudoephedrine to Class B2 will bring it under the provisions of regulation 22 of the Misuse of Drugs Regulations which imposes extremely strict controls on who it may prescribed to. Regulation 22 prohibits the prescription, supply or administration of Class B2 controlled drugs (and Classes A, B1 and C1) except to the extent and in the circumstances approved by the Minister either generally or in relation to any particular case or class of cases. What exemptions will the Minister impose? This question needs serious consideration by the Health Committee and advice given to the Minister to permit its prescription by medical practitioners. Its supply will
3 be prohibited unless the Minister approves the circumstances generally or in relation to particular cases. for its use either We note in the 'Preferred Option' section of the Regulatory Impact Statement to this Bill that "As with other Class B2 controlled drugs, Ministerial approval (delegated to Medsafe) would be required before a medical practitioner could prescribe pseudoephedrine to an individual patient". Is this the intent of the Bill? If so, then it is inconsistent with the statements made by members in the first reading. Speakers to the first reading of the Bill spoke exclusively about the use of pseudoephedrine in treating the symptoms of colds and the flu. Pseudoephedrine has other important therapeutic uses to clear blocked eustachian tubes in the ears of air travellers and underwater divers, and in the treatment of priapism a side effect of treatment with prescribed erectile dysfunction and prostate enlargement (BPH) medicines. Priapism is the presence of a persistent, usually very painful, erection of the penis unrelated to sexual stimulation or desire. It is a medical emergency and pseudoephedrine is the antidote. Before treatment of this adverse event can begin will the Minister or Medsafe have to be contacted to approve its use in the patient? The Expert Advisory Committee on Drugs and Sir Peter Gluckman, the Prime Minister's Science Advisor, have stated that effective alternative remedies to pseudoephedrine are available. The experience of many consumers is that this is not so. We would support greater restrictions if an equally effective oral decongestant with less abuse potential was available to replace it. There is more to P than over the counter pseudoephedrine. The Pharmaceutical Society does wish to point out to the Health Committee that the OTC sale of pseudoephedrine is not the only source of precursor materials for the manufacture of methamphetamine. There is the extensive illegal importation of pseudoephedrine (such as ContacNT) that bypass our border controls, and the supply of the various chemicals and chemical equipment required to convert pseudoephedrine into P. Nor will additional controls on pseudoephedrine affect the illicit manufacture of methamphetamine by other means, such as the reductive amination of P2P (phenyl 2 propanone) through catalytic hydrogenation using Adams Catalyst as described at the Australian National Chemical Diversion Congress November 2008 and at which do not require pseudoephedrine as an ingredient. We note that both pseudoephedrine and ephedrine are already listed as precursor substances in Schedule 4 of the Misuse of Drugs Act Therefore it is currently an offence to knowingly supply them for use in the commission of an offence under the dealing with controlled drugs provisions of the Act. The Pharmaceutical Society believes that implementation in New Zealand of a real time decision support tool such as Project STOP to monitor pharmacy based requests for and sales of pseudoephedrine containing products, would have been the most effective instrument to reduce the illicit diversion of pseudoephedrine for manufacture of methamphetamine, whilst maintaining its availability for those with a legitimate
4 therapeutic need for the medicine. We are disappointed the Government did not accept the very generous offer of the Pharmacy Guild of Australia to provide free of charge for a period of one year access to their Project STOP programme. Project STOP addresses many of the issues and concerns that plague current activities pharmacists undertake to ensure purchases for illegitimate purposes are minimal, while enabling access for genuine therapeutic purposes. By allowing real time evaluation of the identification presented by purchasers, it can provide pharmacists with a level of comfort when deciding whether or not to allow pseudoephedrine sales, and can avoid them making more subjective value judgements based on things such as appearance of the purchaser. The fact that Project STOP enables data immediately to be viewed by all those participating makes the scheme very responsive a most important benefit, both to the next pharmacy down the road and to the Police. The Pharmaceutical Society of New Zealand: 1. Recommends that clauses 6, 7(1), 7(2), 8 and 9 of the Bill be removed. 2. Recommends as an alternative that the exemption requirements for non prescription sale or supply be strengthened by amending in regulation 20 (3)(a) of the Misuse of Drugs Regulations 1977 the reference to 'pharmacy only medicine' to 'restricted medicine' in section 3 of the Medicines Act. This will have the effect of making low dose small packs of pseudoephedrine a 'pharmacist only medicine' with the special legislative responsibilities that controls the sale, record keeping and storage of those medicines. 3. Recommends as a further alternative if the recommendation above is not acceptable, to revoke regulation 20(3) of the Misuse of Drugs Regulations 1977 and, consequently, amend regulation 20(2)(a) and subsection (b) of the partially exempted drug interpretation in regulation 2. This will have the effect of requiring the prescription of an authorised prescriber (such as a medical practitioner, dentist, veterinarian, or designated prescriber authorised to prescribe it) before pseudoephedrine can be supplied or administered to any person. Clause 5 and Clause 10 Removal of Thalidomide as a Class A Controlled Drug The Pharmaceutical Society supports the removal of thalidomide from the Schedules of the Misuse of Drugs Act 1975 and instead schedule it as a prescription medicine under the Medicines Act While it is important there are controls in place for its safe use regarding pregnancy, scheduling it as a Class A controlled drug is not necessary as it has no potential to be misused for a psychoactive effect. The Minister has given consent to its use in New Zealand only with an approved risk management programme in place, which is currently operated by the distributor/sponsor. Whereas previously thalidomide was exempt from the provisions of the drug driving provisions of the Land Transport Act 1998, this amendment and subsequent proposed reclassification by Gazette notice will now capture it under the "any prescription medicine' section (b)(ii) of the definition of a qualifying drug in section 2(1). Is this intended? 4
5 Conclusion Thank you for the opportunity to make a submission. wish to discuss technical aspects of it. I am available should any official Euan Galloway B Pharm, FPS, FHPA, MNZCP, ED Chief Pharmacist Advisor Pharmaceutical Society of New Zealand Inc
How to change the legal classification of a medicine in New Zealand
How to change the legal classification of a medicine in New Zealand Guidance document Medsafe October 2017 Page 1 of 15 Contents Purpose and scope... 3 Definitions... 3 Background and legislative context...
More informationMedicines in Schedule 1 to the Medicines Regulations 1984 that reference the manufacturer s original pack
Medicines in Schedule 1 to the Medicines Regulations 1984 that reference the manufacturer s original pack Appendix 1 1. Name of Alclometasone Restricted; for dermal use in s containing 0.05% or less and
More informationScript for audio: Pseudoephedrine and ephedrine. Audiovisual training for pharmacy support staff
Script for audio: Pseudoephedrine and ephedrine Audiovisual training for pharmacy support staff The aim of this presentation is to provide you with information about the changes that are taking place to
More informationMedicines in Schedule 1 to the Medicine Regulations 1984 that reference the manufacturer s original pack
Medicines in Schedule 1 to the Medicine Regulations 1984 that reference the manufacturer s original pack Information paper for the Medicines Classification Committee Medsafe January 2018 1. Purpose The
More informationCoversheet: Medicinal cannabis: 100 day action
Coversheet: Medicinal cannabis: 100 day action Advising agencies Decision sought Proposing Ministers Ministry of Health Introduction of Misuse of Drugs Amendment Bill Hon Dr David Clark, Minister of Health
More informationPOISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health
POISONS SCHEDULING Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health Topics Schedules of the Poisons Standard (Cth) Poisons and Therapeutic Goods Act 1966
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More information2. The inclusion of public health focused restrictions around the sale and supply of these products.
1 May 2013 Committee Secretariat Health Select Committee Parliament Buildings Wellington Submission on the Psychoactive Substances Bill (RPH) serves the Greater Wellington region, through its three District
More informationInterstate dispensing : A case for uniform, intuitive legislation
Interstate dispensing : A case for uniform, intuitive legislation Author Bernaitis, Nijole, King, Michelle, Hope, Denise Published 2014 Journal Title Journal of Law and Medicine Copyright Statement 2014
More informationPRODUCTS: All products containing ephedrine (EPH) and pseudoephedrine (PSE). (IC )
INDIANA PRODUCTS: All products containing ephedrine (EPH) and pseudoephedrine (PSE). (IC 35-48- 4-14.7) PRODUCT EXEMPTIONS: EPH or PSE products dispensed pursuant to a prescription (IC 35-48-4-14.7); Sale
More informationSupplement No. 1 published with Extraordinary Gazette No. 65 dated 19 th August, 2016.
CAYMAN ISLANDS Supplement No. 1 published with Extraordinary Gazette No. 65 dated 19 th August, 2016. A BILL FOR A LAW TO AMEND THE MISUSE OF DRUGS LAW (2014 REVISION) TO INCLUDE CANNABIS EXTRACTS AND
More informationGetting the best from the medicines you buy
Getting the best from the medicines you buy You can buy many medicines without needing to see your doctor. These are often called over-the-counter medicines. They are safe and effective as long as you
More informationA Proposal for a Trans Tasman Agency to Regulate Therapeutic Products
A Proposal for a Trans Tasman Agency to Regulate Therapeutic Products Discussion Paper June 2002 A PROPOSAL FOR A TRANS TASMAN AGENCY TO REGULATE THERAPEUTIC PRODUCTS DISCUSSION PAPER JUNE 2002 FOREWORD
More informationADVICE TO THE EXPERT ADVISORY COMMITTEE ON DRUGS ON: PSEUDOEPHEDRINE JUNE 2009 PREPARED BY THE MINISTRY OF HEALTH
ADVICE TO THE EXPERT ADVISORY COMMITTEE ON DRUGS ON: PSEUDOEPHEDRINE JUNE 2009 PREPARED BY THE MINISTRY OF HEALTH PURPOSE The Expert Advisory Committee on Drugs (EACD) has requested the secretariat prepare
More informationon the advertising of medicinal products for human use
30. 4. 92 Official Journal of the European Communities No L 113 / 13 COUNCIL DIRECTIVE 92/28/EEC of 31 March 1992 on the advertising of medicinal products for human use THE COUNCIL OF THE EUROPEAN COMMUNITIES,
More informationDrugs and Poisons Legislation Amendment (New Psychoactive and Other Substances) Act 2013 No 70
New South Wales Drugs and Poisons Legislation Amendment (New Psychoactive and Other Substances) Act 2013 No 70 Contents Page 1 Name of Act 2 2 Commencement 2 Schedule 1 Amendment of Drug Misuse and Trafficking
More informationNew regulatory requirements DPCS Regulations 2017
New regulatory requirements DPCS Regulations 2017 Prescribers and pharmacists May 2017 Table of Contents Explanatory notes... 1 Clarifying the meaning of key terms... 1 Chart instructions and prescriptions...
More informationMedicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system
Medicinal cannabis What is medicinal cannabis? Broadly speaking, medicinal cannabis is cannabis prescribed to relieve the symptoms of a medical condition, such as epilepsy. It is important to make the
More information40 Use and Supply of Drugs or Medicines in Optometric Practice
40 Use and Supply of Drugs or Medicines in Optometric Practice Guideline 40.01 The optometrist has a duty to take due care in the use of drugs in optometric practice and to only supply drugs when it is
More informationNon-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients
Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationHome Model Legislation Public Safety and Elections. Methamphetamine Reduction Act
Search GO LOGIN LOGOUT HOME JOIN ALEC CONTACT ABOUT MEMBERS EVENTS & MEETINGS MODEL LEGISLATION TASK FORCES ALEC INITIATIVES PUBLICATIONS NEWS Model Legislation Home Model Legislation Public Safety and
More informationAN OPTIMAL REGULATORY MIX FOR METHAMPHETAMINE PRECURSORS?
AN OPTIMAL REGULATORY MIX FOR METHAMPHETAMINE PRECURSORS? Janet Ransley Griffith University Responding to methamphetamine problems How should governments respond to the problem of domestic, illicit production
More informationChief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS
Chief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS England commissioned services. Chief Dental Officer England:
More informationULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES
APPLICATION FOR RECLASSIFICATION ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES Part A Classification Change Sought 1. International Non-Proprietary name of Medicine fluocortolone pivalate, fluocortolone
More informationOrganization of American States OAS Inter-American Drug Abuse Control Commission CICAD. Multilateral Evaluation Mechanism MEM.
Organization of American States OAS Inter-American Drug Abuse Control Commission CICAD Multilateral Evaluation Mechanism MEM Mexico 2009 EVALUATION OF PROGRESS IN DRUG CONTROL IMPLEMENTATION OF RECOMMENDATIONS
More informationPsychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill
Psychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill 16 1 Report of the Justice Committee September 2018 Contents Recommendation... 2 About the bill as introduced...
More informationI am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the
MINISTERIAL STATEMENT TO THE HOUSE OF ASSEMBLY BY THE HONOURABLE KIM N. WILSON, JP, MP MINISTER OF HEALTH UPDATES AND MODERNIZATION OF DRUG SCHEDULES 24 November 2017 Mr Speaker and Honourable Members,
More informationAct on Narcotic Drugs and Psychotropic Substances and Precursors thereof
Issuer: Riigikogu Type: act In force from: 13.05.2016 In force until: 22.11.2018 Translation published: 06.05.2016 Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof Amended by the
More informationSubmission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No.
Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 Submitted by: Submitted electronically to: Complementary Medicines
More informationPLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.
PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to July 1, 2012. It is intended for information and reference purposes only. This
More informationGisborne District Council Alcohol Control Bylaw 2015
APPENDIX 2 Gisborne District Council Alcohol Control Bylaw 2015 Statement of Proposal May 2015 A569837 Page 1 Introduction This is a Statement of Proposal prepared in accordance with section 83(1)(a) of
More informationMisuse of Drugs (Medicinal Cannabis) Amendment Bill
Misuse of Drugs (Medicinal Cannabis) Amendment Bill Departmental Report Prepared by the Ministry of Health 11 June 2018 1 Contents Introduction... 3 Submissions... 3 Overview... 3 Section One - Key topics
More informationSubmission on the Health (Fluoridation of Drinking Water) Amendment Bill
Auckland Regional Public Health Service Cornwall Complex Floor 2, Building 15 Greenlane Clinical Centre Private Bag 92 605 Symonds Street Auckland 1150 New Zealand Telephone: 09-623 4600 Facsimile: 09-623
More informationMethamphetamine - Oregon Fact Sheet
Methamphetamine - Oregon Fact Sheet In 2005, Oregon shifted away from drug polices based on fear and reaction, and moved toward drug polices based on science and proaction in the areas of Prevention, Enforcement,
More informationHamilton City Council BYLAWS HAMILTON ALCOHOL CONTROL BYLAW 2015
Approved By: Council Date Adopted : 11 August 2010 Date Amended: 16 December 2015 Date Amendment came into force: 20 January 2016 Amendments: Update to include changes to Legislation, Style of bylaw updated
More informationMisuse of Drugs (Changes to Controlled Drugs) Order 2005 and Misuse of Drugs (Presumption of Supply Amphetamine) Order 2005
Misuse of Drugs (Changes to Controlled Drugs) Order 2005 and Misuse of Drugs (Presumption of Supply Amphetamine) Order 2005 Report of the Health Committee Contents Recommendation 2 Introduction 2 Misuse
More informationIssue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES
Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES CONTENTS
More informationMEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH
11 MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH Background The rules in this section are designed to ensure that advertisements that include health claims (please see Section 13 for health claims
More informationResolution 59/8 Promotion of measures to target new psychoactive substances and amphetamine-type stimulants
Resolution 59/8 Promotion of measures to target new psychoactive substances and amphetamine-type stimulants The Commission on Narcotic Drugs, Deeply concerned about the combination of the diversity of
More informationResponse to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014
Responseto ScottishGovernment AConsultationonElectronicCigarettesand StrengtheningTobaccoControlinScotland December2014 Contact Janice Oman Scotland Representation Manager National Pharmacy Association
More informationAlcohol, Tobacco and Other Drugs Minimum Standard. April 2015
Alcohol, Tobacco and Other Drugs Minimum Standard April 2015 Contents 1 Executive Summary... 2 2 More Information... 2 3 Using this Standard... 2 4 Standard Provisions... 2 4.1 Legislative Requirements...
More informationThe Home Office Proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 January 2018
The Home Office Proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 January 2018 Prepared by: Adam Osprey Policy & Development Pharmacist adam.osprey@cps.scot Who
More information29 September Medicines Classification Committee Secretary Medsafe Wellington. Sent via to:
29 September 2017 Medicines Classification Committee Secretary Medsafe Wellington Sent via email to: committees@moh.govt.nz Dear Sir/Madam RE: AGENDA FOR THE 59th MEETING OF THE MEDICINES CLASSIFICATION
More informationConsultation on proposed prescribed qualifications for the General Dental, Oral and Maxillofacial Surgery and Dental Technology Scopes of Practice
16 October 2012 Dear Practitioner, Consultation on proposed prescribed qualifications for the General Dental, Oral and Maxillofacial Surgery and Dental Technology Scopes of Practice Pursuant to section
More informationSMOKING OUTSIDE HOSPITALS: AN OPPORTUNITY TO COMMENT ON PROPOSALS
Population Health Directorate Health Improvement Division T: 0131-244 1707 E: elaine.mitchell@gov.scot Monday, 28 November, 2016 Dear Chief Executive, SMOKING OUTSIDE HOSPITALS: AN OPPORTUNITY TO COMMENT
More informationFederation of Saint Kitts and Nevis
Organization of American States OAS Inter-American Drug Abuse Control Commission CICAD Multilateral Evaluation Mechanism MEM Federation of Saint Kitts and Nevis 2009 EVALUATION OF PROGRESS IN DRUG CONTROL
More informationTHE EXPERT ADVISORY COMMITTEE ON DRUGS (EACD) ADVICE TO THE MINISTER ON:
THE EXPERT ADVISORY COMMITTEE ON DRUGS (EACD) ADVICE TO THE MINISTER ON: BENZYLPIPERAZINE (BZP) April 2004 1 CONTENTS Executive Summary 3 Recommendations 4 Substances identification Similarity to known
More informationGuideline on the Regulation of Therapeutic Products in New Zealand
Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 January 2016 Section 1: Legislation Section summary This
More informationDraft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business
Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business To facilitate compliance with Regulations 5(1)(d), 5(1)(h) and 10 of the Regulation of Retail
More informationTemplate Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices
Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining
More informationNHS Circular: PCA(M)(2011)4 abcdefghijklmnopqrstu TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH SEVERE DISTRESS. Summary
Directorate for Health and Social Care Integration Primary Care NHS Circular: abcdefghijklmnopqrstu Dear Colleague LIST OF DRUGS SUBJECT TO PRESCRIBING TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH
More informationTesting Railway Safety Critical Workers for Drugs and Alcohol
Rail Industry Standard RIS-8070-TOM Issue One Date December 2016 Critical Workers for Drugs and Alcohol Synopsis This document sets out common requirements for drugs and alcohol testing of staff carrying
More informationDRAFT FOR CONSULTATION
DRAFT FOR CONSULTATION Member s Bill Explanatory note Purpose General policy statement The purpose of this Bill is to provide convenient, relevant and readily understood nutrition information and/or guidance
More informationAnimal Products Notice
Animal Products Notice Labelling Requirements for Exports of Dairy Based Infant Formula Products and Formulated Supplementary Food for Young Children 18 December 2014 An animal products notice issued under
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationUnit title: Legal and Social Responsibilities of a Personal Licence Holder
Unit Specification for Regulated Qualifications General information Unit title: Legal and Social Responsibilities of a Personal Licence Holder Unit Level: 2 Credit: 1 Guided Learning Hours: 1 SQA Unit
More informationFACT SHEET PREPARED BY THE MINISTRY OF JUSTICE ON THE DANGEROUS DRUGS (AMENDMENT) ACT 2015 OVERVIEW 1. This Fact Sheet sets out the main changes that have been made to the Dangerous Drugs Act (the DDA
More informationIn Confidence. Office of the Associate Minister Health. Chair, Social Policy Committee. Regulation of smokeless tobacco and nicotine-delivery products
In Confidence Office of the Associate Minister Health Chair, Social Policy Committee Regulation of smokeless tobacco and nicotine-delivery products Proposal 1 This paper seeks approval to prepare and issue
More informationTobacco Free Ireland Action Plan
Tobacco Free Ireland Action Plan Tobacco Free Ireland, the report of the Tobacco Policy Review Group, was endorsed by Government, and published in October 2013. It builds on existing tobacco control policies
More informationTHE RESPONSIBLE PHARMACIST REGULATIONS
THE RESPONSIBLE PHARMACIST REGULATIONS A SUMMARY OF THE RESPONSES TO PUBLIC CONSULTATION ON PROPOSALS FOR THE CONTENT OF THE REGULATIONS DH INFORMATION READER BOX Policy HR / Workforce Management Planning
More informationAustralian and New Zealand College of Anaesthetists (ANZCA) Submission to Misuse of Drugs (Medicinal Cannabis) Amendment Bill Page 0
Page 0 Table of contents Page 1. Executive Summary 2 2. About ANZCA 3 3. About FPM 4 4. ANZCA response to the Misuse of Drugs (Medicinal Cannabis) Amendment Bill 5 4.1 ANZCA Position on medicinal cannabis
More informationWorkplace Drug and Alcohol Policy
Workplace Drug and Alcohol Policy January 2017 This Drug and Alcohol Policy is intended for and includes but is not limited to all Students, Contractors and all others either directly or indirectly engaged
More informationREQUEST FOR PROPOSALS SUPPLY OF NICOTINE REPLACEMENT THERAPY
16 October 2013 Dear Supplier REQUEST FOR PROPOSALS SUPPLY OF NICOTINE REPLACEMENT THERAPY PHARMAC invites proposals for the supply of nicotine replacement therapy (including, but not limited to, nicotine
More informationOn 24 April 2012, FSANZ sought submissions on a draft variation and published an associated report. FSANZ received seven submissions.
26 September 2012 [22-12] Approval Report Application A1068 Hydrogen Peroxide as a Processing Aid Food Standards Australia New Zealand (FSANZ) has assessed an Application made by Fonterra Co-operative
More informationPage 1 of 5 About Contact Info Feedback Site Map Help Related Subsidiary Legislation Legislative History Amendment Annotation off Search Within All Government Websites Go Home Search Browse Results My
More informationImproving safety for patients taking an ACE inhibitor/arb + diuretic
CLINICAL AUDIT Improving safety for patients taking an ACE inhibitor/arb + diuretic Valid to May 2023 bpac nz better medicin e Background Angiotensin converting enzyme (ACE) inhibitors, angiotensin- II
More informationDrug and Alcohol Policy
Drug and Alcohol Policy Purpose Skillset Pty Ltd ( Skillset ) is committed to providing a safe and healthy work environment, so far as is reasonably practicable in which all workers are treated fairly,
More informationUNIVERSITY STATEMENT FOR STUDENTS ON SUBSTANCE USE/MISUSE
UNIVERSITY STATEMENT FOR STUDENTS ON SUBSTANCE USE/MISUSE HEALTH & SAFETY UNIT AUTUMN 2012 CONTENTS 1 AIM... 2 2 APPLICATION... 2 3 DEFINITIONS... 2 4 EDUCATION AND AWARENESS RAISING... 2 5 PROVISION OF
More informationProgressing Safely in OTC Switch. Dr Natalie Gauld ASMI presentation Nov 2015
Progressing Safely in OTC Switch Dr Natalie Gauld ASMI presentation Nov 2015 Outcomes of progressive switches considered in NZ & Australia in 2000-2011 New Zealand doi:10.1371/journal.pone.0119011.g001
More informationGuide to Professional Conduct and Ethics for Registered Medical Practitioners. Relationships between doctors and industry Frequently Asked Questions
Guide to Professional Conduct and Ethics for Registered Medical Practitioners Relationships between doctors and industry Frequently Asked Questions Partnership Practice Performance Relationships between
More informationPHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.
PHOLCODINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains pholcodine. This leaflet is intended to provide information on the active ingredient
More information(Reprinted with amendments adopted on April 26, 2011) FIRST REPRINT S.B. 335 MARCH 21, Referred to Committee on Health and Human Services
(Reprinted with amendments adopted on April, 0) FIRST REPRINT S.B. SENATE BILL NO. SENATORS PARKS AND HARDY (BY REQUEST) MARCH, 0 JOINT SPONSORS: ASSEMBLYMEN PIERCE; AND OHRENSCHALL Referred to Committee
More informationORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION
ORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION FORTY-FOURTH REGULR SESSION November 19 21, 2008 Santiago, Chile OAS/Ser.L/XIV.2.44 CICAD/doc.1708/08 20 November 2008 Original:
More informationSTATUTORY INSTRUMENTS. S.I. No. 599 of 2015 HEALTH PRODUCTS REGULATORY AUTHORITY (FEES) REGULATIONS 2015
STATUTORY INSTRUMENTS. S.I. No. 599 of 2015 HEALTH PRODUCTS REGULATORY AUTHORITY (FEES) REGULATIONS 2015 2 [599] S.I. No. 599 of 2015 HEALTH PRODUCTS REGULATORY AUTHORITY (FEES) REGULATIONS 2015 I, KATHLEEN
More informationHome Office Circular 001 / 2009 Controlled Drugs: Reclassification Of Cannabis
Home Office Circular 001 / 2009 Page 1 of 4 Printer Friendly Version A Close Window EM Home Office 6i, i:. a,si1 a awl 11,+11 ",V 1WGSaAM, UX In Issue Date: 15/01/2009 Implementation Date: 26/01/2009 Home
More informationProposed Radiation Safety Regulations: Submission form
Proposed Radiation Safety Regulations: Submission form Making a submission This form is designed to assist submitters responding to the discussion points in Proposed Radiation Safety Regulations: A consultation
More informationREAL TIME MONITORING OF PRESCRIPTION MEDICINES BEING A HEALTHY STATE
BEING A HEALTHY STATE 2036 WILL MARK OUR STATE S BICENTENARY By the time our State turns 200 years old, I want South Australia to be a place of prosperity. Planning and delivering on my vision for a better
More informationRingwood School Drug, Alcohol and Substance Misuse Policy
Ringwood School Drug, Alcohol and Substance Misuse Policy POLICY DETAILS Policy Name Policy Category Policy Number & Version Drug, alcohol and substance misuse policy Guidance and Achievement January 2017
More information1. Introduction. 2. Role of PSI as Pharmacy Regulator
1. Introduction 1.1. I would like to begin by thanking the Committee for inviting the Pharmaceutical Society of Ireland here today to assist in the Committee s on-going scrutiny of the Cannabis for Medicinal
More informationImproving the regulatory framework for electronic cigarettes (e-cigarettes) and emerging tobacco and nicotine-delivery products
[In Confidence] Office of the Associate Minister Health Chair, Cabinet Improving the regulatory framework for electronic cigarettes (e-cigarettes) and emerging tobacco and nicotine-delivery products Proposal
More informationJanuary 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9
January 19, 2018 Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9 By email: cannabis@canada.ca RE: Proposed Approach to the Regulation of Cannabis
More informationThe Nutrition (Amendment) (EU Exit) Regulations 2018
The Nutrition (Amendment) (EU Exit) Regulations 2018 A public consultation Contents Introduction... 3 Why we are consulting... 4 Nutrition and Health Claims... 6 Proposals... 6 Vitamins, minerals, and
More informationDevelopments in regulations for complementary medicines (including traditional medicines and other natural health products)
Developments in regulations for complementary medicines (including traditional medicines and other natural health products) A/Professor Jo Barnes BPharm (Hons) PhD RegPharmNZ MPSNZ FLS School of Pharmacy,
More informationProvincially-Licensed Cannabis Retail Stores in Toronto
CC1.4 REPORT FOR ACTION Provincially-Licensed Cannabis Retail Stores in Toronto Date: December 6, 2018 To: City Council From: City Manager Wards: All SUMMARY Provincially-licensed private cannabis retail
More informationSafe Prescribing and Dispensing of Controlled Drugs. Joint Guidance Medical Council and Pharmaceutical Society of Ireland
Safe Prescribing and Dispensing of Controlled Drugs Joint Guidance Medical Council and Pharmaceutical Society of Ireland Purpose of this Guidance Purpose of this Guidance This resource aims to facilitate
More informationGuidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business
Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business to Facilitate Compliance with Regulations 5(1)(g), 6, 8 and 11 of the Regulation of Retail Pharmacy Businesses
More informationSUBMISSION FOR RECLASSIFICATION
SUBMISSION FOR RECLASSIFICATION SOLANACEOUS PLANTS AND ALKLAOIDS ATROPA BELLADONNA ATROPINE HYOSCINE HYOSCYAMINE HYOSCYAMUS NIGER Request for a change to the level for exemption from scheduling For the
More informationPrescription only medicines (POMs)
Prescription only medicines (POMs) 2017 Learning objectives Explain the legal framework with which registered health care professionals can administer prescription only medicines Define the role and limitations
More informationThe Regulatory Environment in New Zealand. Michelle Palmer Natural Products New Zealand
The Regulatory Environment in New Zealand Michelle Palmer Natural Products New Zealand Nieuw Zeeland You are here New Zealand? It s where? Unique Product Offerings Botanical Origin Manuka honey Horopito
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationRELEASED UNDER THE OFFICIAL INFORMATION ACT 1982
Priority Medium Security Level In Confidence Distribution Minister Minister s Advisor Minister s Office 26 January 2018 Document Number: B17-0832 Forum on Food Regulation Out-of-Session Response: Food
More informationRecall Guidelines. for Chinese Medicine Products
Recall Guidelines for Chinese Medicine Products April 2018 Recall Guidelines for Chinese Medicine Products Chinese Medicines Board Chinese Medicine Council of Hong Kong Compiled in September 2005 1 st
More informationExplanatory Notes Relating to Regulatory and Legislative Proposals Relating to the Taxation of Cannabis
Explanatory Notes Relating to Regulatory and Legislative Proposals Relating to the Taxation of Cannabis Published by The Honourable William Francis Morneau, P.C., M.P. Minister of Finance September 2018
More informationDraft Broadcasting Services (Television Captioning) Standard 2013
Draft Broadcasting Services (Television Captioning) Standard 2013 Submission by the Australian Communications Consumer Action Network to the Australian Communications and Media Authority 22 January 2013
More informationDate Marking. User Guide. Standard Date Marking of Food. December 2013
Date Marking User Guide to Standard 1.2.5 Date Marking of Food December 2013 Contents Contents... ii Background... 1 Food Standards in Australia and New Zealand... 1 Responsibility of food businesses...
More informationINQUIRY INTO USE OF CANNABIS FOR MEDICAL
Submission No 58 INQUIRY INTO USE OF CANNABIS FOR MEDICAL PURPOSES Organisation: NSW Council for Civil Liberties Date received: 15/02/2013 The NSW Council for Civil Liberties considers that drug use should
More informationCitation: Ministry of Health Consultation on Proposed Amendments to Regulations under the Medicines Act Wellington: Ministry of Health.
Consultation on Proposed Amendments to Regulations under the Medicines Act 1981 Citation: Ministry of Health. 2010. Consultation on Proposed Amendments to Regulations under the Medicines Act 1981. Wellington:
More informationPetition 2014/15 of Anthony Roberts and 40 others
Petition 2014/15 of Anthony Roberts and 40 others Report of the Health Committee Contents Recommendation 2 Background 2 The petitioner s concerns 3 Best practice and international benchmarks 4 Ministry
More informationPATIENT SAFETY ALERT
PATIENT SAFETY ALERT PROBLEM: Research in UK and elsewhere has identified a risk to patients from errors occurring during intravenous administration of potassium solutions. Potassium chloride concentrate
More information